RS57711B1 - Novi oksintomodulin derivativi i farmaceutiske kompozicije za tretman gojaznosti, koje ga sadrže - Google Patents

Novi oksintomodulin derivativi i farmaceutiske kompozicije za tretman gojaznosti, koje ga sadrže

Info

Publication number
RS57711B1
RS57711B1 RS20181080A RSP20181080A RS57711B1 RS 57711 B1 RS57711 B1 RS 57711B1 RS 20181080 A RS20181080 A RS 20181080A RS P20181080 A RSP20181080 A RS P20181080A RS 57711 B1 RS57711 B1 RS 57711B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
same
treating obesity
oxyntomodulin derivatives
novel
Prior art date
Application number
RS20181080A
Other languages
English (en)
Inventor
Sung Youb Jung
Myung Hyun Jang
Ling Ai Shen
Young Kyung Park
Young Jin Park
Se Chang Kwon
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47296599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57711(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of RS57711B1 publication Critical patent/RS57711B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20181080A 2011-06-10 2012-06-07 Novi oksintomodulin derivativi i farmaceutiske kompozicije za tretman gojaznosti, koje ga sadrže RS57711B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110056472 2011-06-10
PCT/KR2012/004494 WO2012169798A2 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
EP12797363.4A EP2718318B1 (en) 2011-06-10 2012-06-07 Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Publications (1)

Publication Number Publication Date
RS57711B1 true RS57711B1 (sr) 2018-12-31

Family

ID=47296599

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20181080A RS57711B1 (sr) 2011-06-10 2012-06-07 Novi oksintomodulin derivativi i farmaceutiske kompozicije za tretman gojaznosti, koje ga sadrže

Country Status (30)

Country Link
US (4) US9527898B2 (sr)
EP (3) EP3878859B1 (sr)
JP (5) JP6014127B2 (sr)
KR (2) KR101502299B1 (sr)
CN (1) CN103732618B (sr)
AR (1) AR086866A1 (sr)
AU (4) AU2012267398B2 (sr)
BR (2) BR122020011001B1 (sr)
CA (2) CA3064214C (sr)
CL (1) CL2013003547A1 (sr)
CY (1) CY1120781T1 (sr)
DK (3) DK3434687T3 (sr)
ES (3) ES2692187T3 (sr)
HR (1) HRP20181591T1 (sr)
HU (1) HUE040307T2 (sr)
IL (3) IL245557B (sr)
LT (1) LT2718318T (sr)
MX (2) MX350708B (sr)
MY (1) MY169309A (sr)
PE (3) PE20240686A1 (sr)
PL (1) PL2718318T3 (sr)
PT (1) PT2718318T (sr)
RS (1) RS57711B1 (sr)
RU (2) RU2739209C2 (sr)
SG (2) SG10201604564XA (sr)
SI (1) SI2718318T1 (sr)
TW (2) TWI674271B (sr)
UA (2) UA114710C2 (sr)
WO (1) WO2012169798A2 (sr)
ZA (1) ZA201309054B (sr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
EP2721062B1 (en) * 2011-06-17 2018-11-14 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
ES2748158T3 (es) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
AR098614A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
AR098615A1 (es) * 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
MA43289B1 (fr) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
CN117065044A (zh) 2014-03-31 2023-11-17 韩美药品株式会社 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CA2972748A1 (en) * 2014-12-30 2016-07-07 Hanmi Pharm. Co., Ltd. Glucagon derivative having improved stability
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
DK3322437T3 (da) * 2015-06-30 2024-03-25 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EA038544B1 (ru) 2015-12-31 2021-09-13 Ханми Фарм. Ко., Лтд. Тройной агонист рецепторов глюкагона/glp-1/gip
SG11201810102SA (en) * 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
IL263934B2 (en) * 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd A derivative of glucagon, its conjugate, a preparation containing it and its medical use
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
WO2018105988A1 (ko) 2016-12-05 2018-06-14 한미약품 주식회사 면역반응이 약화된 결합체
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
AU2018215840A1 (en) 2017-02-03 2019-08-01 Hanmi Pharm. Co., Ltd. Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
EP3823659A4 (en) 2018-07-19 2022-06-22 D&D Pharmatech Inc. PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
US11970523B2 (en) * 2018-07-25 2024-04-30 China Pharmaceutical University Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof
CA3115193A1 (en) * 2018-10-04 2020-04-09 Hanmi Pharm. Co., Ltd. Therapeutic uses of glucagon and combined product comprising same
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
KR20240053545A (ko) * 2022-10-14 2024-04-24 한미약품 주식회사 신규한 glp-1 수용체 길항제 및 이를 포함하는 선천성 고인슐린증 또는 저혈당증의 예방 또는 치료용 약학적 조성물

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU749815B2 (en) 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
AU2005311099B2 (en) 2004-12-02 2012-02-02 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
PT1891105E (pt) * 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1991574B1 (en) * 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
WO2009009562A2 (en) 2007-07-10 2009-01-15 Eli Lilly And Company Glp-1-fc fusion protein formulation
AU2008306190A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of bubuc and optionally EAA-MART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US20120121591A1 (en) 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
CA2755395C (en) 2009-03-20 2015-02-24 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
RU2559320C2 (ru) 2010-03-26 2015-08-10 Ново Нордиск А/С Новые аналоги глюкагона
CN103179976A (zh) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
JP2014501762A (ja) 2010-12-22 2014-01-23 マルケイディア バイオテック， インコーポレイテッド Ｇｉｐおよびｇｌｐ−１受容体活性グルカゴン系ペプチドにより代謝障害および肥満を治療するための方法
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
ES2692187T3 (es) * 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
EP2721062B1 (en) 2011-06-17 2018-11-14 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
ES2748158T3 (es) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法

Also Published As

Publication number Publication date
NZ731342A (en) 2017-09-29
KR20120137271A (ko) 2012-12-20
EP3878859B1 (en) 2023-11-01
PT2718318T (pt) 2018-11-09
AU2012267398B2 (en) 2016-10-13
HRP20181591T1 (hr) 2018-11-30
RU2017105866A (ru) 2019-01-23
NZ748012A (en) 2020-01-31
KR20140130659A (ko) 2014-11-11
US9522946B2 (en) 2016-12-20
CA2838503C (en) 2020-02-18
CA3064214A1 (en) 2012-12-13
CY1120781T1 (el) 2019-12-11
BR112013031794B1 (pt) 2020-11-10
EP2718318A2 (en) 2014-04-16
UA114710C2 (uk) 2017-07-25
US20150291679A1 (en) 2015-10-15
JP2020183433A (ja) 2020-11-12
TW201803895A (zh) 2018-02-01
TWI619724B (zh) 2018-04-01
MX2022004041A (es) 2022-08-10
JP2017043624A (ja) 2017-03-02
BR112013031794A2 (pt) 2016-12-20
US9527898B2 (en) 2016-12-27
AU2012267398A1 (en) 2014-01-16
AU2018213964B2 (en) 2020-03-19
ES2875748T3 (es) 2021-11-11
EP3434687A3 (en) 2019-02-20
LT2718318T (lt) 2018-10-25
JP7094327B2 (ja) 2022-07-01
NZ717174A (en) 2017-07-28
RU2017105866A3 (sr) 2020-06-26
IL268984A (en) 2019-10-31
JP2018117629A (ja) 2018-08-02
ZA201309054B (en) 2014-08-27
UA126465C2 (uk) 2022-10-12
TWI674271B (zh) 2019-10-11
DK3878859T3 (da) 2024-01-02
RU2013154066A (ru) 2015-07-20
CL2013003547A1 (es) 2014-06-27
JP6014127B2 (ja) 2016-10-25
CN103732618A (zh) 2014-04-16
KR101573636B1 (ko) 2015-12-03
RU2739209C2 (ru) 2020-12-21
US20170022261A1 (en) 2017-01-26
EP2718318A4 (en) 2014-12-31
IL260582B (en) 2019-09-26
NZ618810A (en) 2016-03-31
US9765131B2 (en) 2017-09-19
ES2968043T3 (es) 2024-05-06
DK3434687T3 (da) 2021-06-07
PE20181299A1 (es) 2018-08-09
AU2020201322B2 (en) 2021-04-29
JP6862493B2 (ja) 2021-04-21
SG10201604564XA (en) 2016-07-28
JP2019189611A (ja) 2019-10-31
WO2012169798A2 (en) 2012-12-13
AU2016273908B2 (en) 2018-08-23
CA3064214C (en) 2023-03-07
SI2718318T1 (sl) 2018-11-30
EP2718318B1 (en) 2018-07-25
NZ755534A (en) 2020-10-30
AU2016273908A1 (en) 2017-01-12
JP2014516566A (ja) 2014-07-17
US10442848B2 (en) 2019-10-15
AU2020201322A1 (en) 2020-03-12
ES2692187T3 (es) 2018-11-30
EP3878859A1 (en) 2021-09-15
KR101502299B1 (ko) 2015-03-11
BR122020011001B1 (pt) 2022-09-20
CN103732618B (zh) 2018-10-09
SG195258A1 (en) 2013-12-30
RU2612906C2 (ru) 2017-03-13
US20170342122A1 (en) 2017-11-30
IL268984B (en) 2021-04-29
PE20240686A1 (es) 2024-04-10
IL245557A0 (en) 2016-06-30
MY169309A (en) 2019-03-21
MX2013014468A (es) 2014-05-13
NZ740049A (en) 2019-05-31
WO2012169798A3 (en) 2013-02-14
PE20140765A1 (es) 2014-06-14
EP3434687B1 (en) 2021-03-10
IL245557B (en) 2018-12-31
TW201307380A (zh) 2013-02-16
EP3434687A2 (en) 2019-01-30
NZ734808A (en) 2018-11-30
PL2718318T3 (pl) 2019-02-28
US20140128318A1 (en) 2014-05-08
CA2838503A1 (en) 2012-12-13
HUE040307T2 (hu) 2019-02-28
DK2718318T3 (en) 2018-11-05
JP6312765B2 (ja) 2018-04-18
MX350708B (es) 2017-09-14
AR086866A1 (es) 2014-01-29
AU2018213964A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
IL268984B (en) Derivatives of oxyntomodulin and a pharmaceutical preparation containing them for the treatment of obesity
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
RS61827B1 (sr) Farmaceutska kompozicija, postupci za lečenje i njihova primena
IL228771A0 (en) Glycoside history and their use in the treatment of diabetes
EP2558103A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
ZA201209674B (en) Pharmaceutical compositions comprising paracetamol and process for preparing the same
HK1178044A1 (en) Pharmaceutical composition for treating drug addiction
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
EP2730288A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS
EP2629767A4 (en) BENZENE-SULFONANILIDE AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND METHOD OF TREATING CANCER USING SAME
HUP1100534A2 (en) Pharmaceutical composition for the treatment of muscle atrophy
HK1213809A1 (zh) 用於治療肥胖症的藥物組合物
PL393254A1 (pl) Nowe pochodne betuliny i sposób ich otrzymywania
PL390328A1 (pl) Sulfotlenek oraz sposób jego otrzymywania